Ionis Pharmaceuticals Inc
$ 56.56
3.80%
07 Aug - close price
- Market Cap 9,399,385,000 USD
- Current Price $ 56.56
- High / Low $ 56.60 / 54.40
- Stock P/E N/A
- Book Value 2.65
- EPS -3.48
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -1.06 %
- 52 Week High 86.74
- 52 Week Low 40.37
About
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
Analyst Target Price
$89.33
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-29 | 2026-04-29 | 2026-02-25 | 2025-10-29 | 2025-07-30 | 2025-04-30 | 2025-02-19 | 2024-11-06 | 2024-08-01 | 2024-05-07 | 2024-02-21 | 2023-11-02 |
| Reported EPS | -0.7 | -0.3 | -1.1481 | -0.61 | 0.85 | -0.92 | -0.4304 | -0.95 | -0.24 | -0.77 | -0.06 | -0.85 |
| Estimated EPS | -1.09 | -0.77 | -1.33 | -1.05 | 0.16 | -1.03 | -0.8444 | -1.16 | -0.76 | -0.83 | -0.83 | -0.89 |
| Surprise | 0.39 | 0.47 | 0.1819 | 0.44 | 0.69 | 0.11 | 0.414 | 0.21 | 0.52 | 0.06 | 0.77 | 0.04 |
| Surprise Percentage | 35.7798% | 61.039% | 13.6767% | 41.9048% | 431.25% | 10.6796% | 49.0289% | 18.1034% | 68.4211% | 7.2289% | 92.7711% | 4.4944% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.186 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 | $0.11 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IONS
2026-08-07 16:41:00
Dimensional Fund Advisors LP increased its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 51.8% in the first quarter, now owning 267,215 shares valued at approximately $20.1 million. Despite this institutional buying, the company faces profitability concerns with analysts expecting continued losses. Ionis Pharmaceuticals maintains a "Moderate Buy" consensus rating from analysts, though several have recently lowered their price targets and earnings forecasts.
2026-08-07 03:12:15
Pomerantz LLP is investigating potential claims on behalf of investors of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) following a significant stock drop. The investigation stems from Ionis's disclosure that its late-stage Phase-3 CARDIO-TTransform trial for Wainua, an amyloid cardiomyopathy treatment, failed to meet its primary endpoint, leading to a 23.9% decline in stock price on July 9, 2026. The firm encourages affected investors to contact them regarding possible securities fraud or unlawful business practices.
2026-08-05 16:41:00
Ionis Pharmaceuticals is a leading developer of antisense technology, focusing on a broad pipeline of drugs for various diseases, including cardiovascular, metabolic, neurological, and rare conditions. The article highlights early signs of commercial momentum for Tryngolza, with key catalysts approaching for the company. The current stock price is $56.56, and investors are encouraged to upgrade for detailed reports and insights.
2026-08-04 16:41:00
Ionis Pharmaceuticals' Independent Director, Michael Hayden, recently purchased US$1.1m worth of stock, increasing his holding by 34%. While there was significant insider selling over the past year by the Founder, Brett Monia, this occurred at a higher price than the current stock value. Insiders collectively own 0.8% of the company, indicating some alignment with shareholder interests despite more selling than buying in the last year.
2026-08-04 11:09:56
Ionis Pharmaceuticals' Independent Director, Michael Hayden, recently purchased US$1.1m worth of stock, increasing his holding by 34%. While there have been more insider sales than purchases over the past year, insiders still own 0.8% of the company, valued at US$69m, indicating some alignment with shareholder interests. The recent buying activity suggests a positive outlook from at least one key insider.
2026-08-04 02:09:56
Ionis Pharmaceuticals director Michael R. Hayden purchased 20,000 shares for $1.1 million, increasing his total holdings by 34%. This insider buying signals strong confidence in the company's future, especially given its focus on RNA-targeted therapies and a promising drug pipeline. The transaction comes as Ionis Pharmaceuticals, valued at $8.8 billion, continues to advance its treatments for rare genetic and neurological disorders.
